Report Highlights

Neuromarketing technology at a turning point: Market Overview

The global neuromarketing technology market stood at USD 2.1 billion in 2024, propelled by sustained corporate investment in understanding the subconscious drivers of consumer behaviour. The market has evolved significantly from its academic origins: enterprise-grade platforms now integrate EEG, eye-tracking, galvanic skin response, and facial action coding into unified analytics dashboards accessible to brand teams without neuroscience expertise. Sectors including packaged goods, automotive, media, and financial services have all institutionalised neuromarketing as a complement to conventional survey-based research, with adoption rates highest among Fortune 500 marketing departments seeking to reduce advertising waste and sharpen creative effectiveness metrics.

The current moment marks a decisive inflection driven by two converging forces: the collapse of third-party cookie infrastructure, which has stripped digital marketers of their primary behavioural data source, and the commercialisation of affordable AI-powered emotion recognition software that removes the need for expensive laboratory infrastructure. Companies like Neurons Inc. have demonstrated that predictive attention scoring — powered by machine learning trained on neuroimaging datasets — can be delivered entirely through a software interface, lowering the entry barrier for mid-market advertisers. This democratisation of neurological insight is restructuring the competitive landscape and redirecting investment from hardware-dependent methodologies toward scalable SaaS-based platforms.

Key forces shaping neuromarketing technology growth

Three structural forces are driving revenue expansion. First, the global deprecation of third-party cookies by Google, now confirmed for Chrome in 2025, compels brands to build proprietary understanding of consumer psychology through direct measurement rather than inferred digital tracking. This regulatory shift disproportionately benefits neuromarketing platform providers, particularly those offering real-time in-store and digital ad testing capabilities, as brands redirect data budgets toward first-party neurological and biometric insight generation. The FMCG and retail segments in North America and Western Europe are the primary revenue beneficiaries of this specific transition.

Second, AI integration is dramatically expanding what neuromarketing platforms can deliver from a single data capture session, multiplying software revenue per client engagement. Companies such as iMotions now synthesise eye-tracking, EEG, and facial expression data simultaneously, producing unified engagement scores that were previously impossible without specialist neuroscientists on staff. Third, the growth of streaming media and connected TV advertising has created intense demand for creative pre-testing tools that go beyond recall metrics. Platforms offering frame-by-frame neurological attention mapping for video content — a capability Neurons Inc. markets aggressively to media agencies — are growing at above-market rates within the broader neuromarketing segment.

Barriers and risks in the neuromarketing technology market

The most consequential structural barrier is the absence of standardised measurement protocols across the industry. Unlike clinical neuroimaging, neuromarketing lacks a governing body that certifies methodology, meaning that EEG-derived engagement scores from Emotiv and Nielsen Consumer Neuroscience are not directly comparable. This fragmentation inhibits enterprise procurement, particularly among risk-averse regulated industries such as pharmaceuticals and financial services, where marketing claims must survive legal scrutiny. Until a de facto industry standard emerges — likely catalysed by a major platform consolidation event — buyers remain sceptical about cross-vendor data validity, which places a ceiling on deal sizes and contract renewal rates.

The cyclical risk is more immediate: neuromarketing tools are discretionary marketing research expenditures, making them acutely sensitive to brand budget cuts during economic slowdowns. The 2023 correction in global advertising spend, which saw major CPG companies including Procter and Gamble reduce agency and research vendor budgets by an average of 8%, demonstrated that neuromarketing contracts are among the first to be renegotiated or deferred. This cyclical vulnerability is more dangerous to the near-term growth thesis than the structural standardisation problem, because a macroeconomic shock in 2025 or 2026 would directly interrupt the adoption ramp that underpins the 14.1% CAGR projection.

Emerging opportunities in neuromarketing technology

The most credible near-term opportunity lies in the intersection of neuromarketing and e-commerce UX optimisation. As direct-to-consumer brands scale their digital storefronts, eye-tracking and implicit association testing are being embedded directly into product page A/B testing workflows. Tobii's integration with Figma-based design environments and Neurons Inc.'s API-accessible attention prediction model both position their respective vendors to capture recurring SaaS revenue from product and UX teams, not just marketing research departments. This opportunity materialises fully once platform integrations with major e-commerce infrastructure providers — Shopify and Adobe Commerce — are live and verified at scale.

A second opportunity with substantial revenue potential is the application of neuromarketing tools to political and public health communication, particularly in emerging markets where traditional focus group infrastructure is weak. Governments and international health organisations in South Asia and Sub-Saharan Africa are beginning to commission neuromarketing audits of vaccination messaging and public safety campaigns, a use case that requires culturally adapted emotional baseline data. This segment requires vendors to build localised neurological response databases — a one-time investment that creates durable competitive moats — and becomes commercially viable once pilot programme results are published and procurement frameworks are formalised, expected by late 2026.

Investment case: Bull, bear, and what decides it

The bull case rests on three simultaneous catalysts: the full activation of cookie-free digital advertising by end-2025, continued AI cost compression that brings neurological testing within reach of mid-market budgets, and a wave of platform consolidation that concentrates revenue among three to five scaled vendors commanding premium multiples. Under this scenario, the market grows ahead of the base CAGR as enterprise software attach rates accelerate and recurring subscription revenue displaces project-based billing. Investors entering positions in AI-integrated neuromarketing platforms before consolidation closes will capture disproportionate upside, particularly in companies with proprietary neuroimaging training datasets that cannot be replicated by new entrants.

The bear case is activated by a combination of macroeconomic pressure on discretionary marketing budgets and a regulatory crackdown on biometric data collection. The EU's evolving interpretation of GDPR Article 9 — which classifies neurological and biometric data as sensitive personal data — already constrains how European operators can collect and store EEG and facial coding outputs. If the European Data Protection Board issues binding guidance that imposes explicit consent requirements for neuromarketing data capture in commercial settings, European revenue — currently representing 28% of the global total — faces material contraction, and the broader industry narrative of scalable mass-market neuromarketing collapses.

The single swing variable is GDPR enforcement posture toward biometric data. If European regulators treat commercial neuromarketing data collection as categorically equivalent to medical biometric processing — triggering Article 9 explicit consent requirements — the SaaS scaling model breaks, because opt-in rates in commercial research settings will not sustain statistically valid sample sizes at acceptable cost. Conversely, if regulators issue guidance that exempts pseudonymised aggregate neuromarketing outputs from the strictest consent tiers, the European market re-opens at scale. This regulatory call, not AI capability or macroeconomics, is the decisive variable for the 2026–2028 growth window.

Market at a Glance

Regional performance: Where neuromarketing technology is growing fastest

North America is the largest revenue contributor, accounting for an estimated 41% of the 2024 global market, driven by dense concentrations of FMCG headquarters, major media agencies, and a mature marketing research infrastructure in New York, Chicago, and San Francisco. U.S. brands have the highest per-engagement spend on neuromarketing research, and the presence of Nielsen Consumer Neuroscience and Neurons Inc. as domestically headquartered vendors reinforces local procurement preference. Europe is the second-largest market but faces the regulatory headwinds described above, with Germany, the UK, and France representing the bulk of regional revenue.

Asia Pacific is the fastest-growing region, expanding at a CAGR above 18%, led by China, South Korea, and Japan. Chinese technology platforms including ByteDance and Alibaba have begun integrating biometric consumer research into their advertising effectiveness units, creating large-enterprise demand for neuromarketing infrastructure at a scale not seen elsewhere. South Korea's concentration of global consumer electronics and beauty conglomerates — Samsung, LG, and AmorePacific — drives regional adoption of in-lab EEG and eye-tracking protocols for product packaging and UX design. Latin America and the Middle East and Africa remain nascent but are projected to accelerate post-2027 as domestic advertising markets mature and government-commissioned neuromarketing pilots generate documented ROI benchmarks.

Leading Market Participants

• Nielsen Consumer Neuroscience
• Tobii AB
• Emotiv
• iMotions
• Neurons Inc.
• Ipsos
• Neurensics
• SR Research
• Bitbrain
• Qualtrics (XM Discover)

Where is neuromarketing technology headed by 2034

By 2034, the neuromarketing technology market will reach USD 7.8 billion and will look structurally different from today. The fragmented vendor landscape of 2024 — characterised by dozens of single-method specialists — will have consolidated into a smaller field of integrated platform providers offering full biometric stacks under subscription pricing models. The dominant technology will not be hardware-led: AI-powered predictive attention and emotion models, trained on decades of accumulated neuroimaging data, will deliver most commercial neuromarketing insights without requiring physical sensor deployment, reducing the cost per insight by an order of magnitude relative to current laboratory-based methods.

The companies best positioned for 2034 are those currently building proprietary neurological response datasets at scale — specifically Neurons Inc. and iMotions, whose platform breadth generates continuous training data across geographies and stimulus categories. Tobii AB's hardware dominance remains valuable but increasingly faces margin pressure as software-only alternatives reduce the necessity of physical eye-tracking infrastructure for mid-tier research use cases. Emotiv's positioning in portable, consumer-accessible EEG gives it a credible path into wearable neuromarketing applications as brain-computer interface adoption broadens. Vendors that fail to build software-defined revenue streams before 2027 will face irrelevance as AI-native competitors bypass the hardware layer entirely.

Market Segmentation

By Technology

• Electroencephalography (EEG)
• Eye-Tracking
• Functional MRI (fMRI)
• Facial Coding
• Galvanic Skin Response
• AI-Powered Predictive Analytics

By Application

• Advertising and Creative Testing
• Product Design and Packaging
• Retail and Shopper Behaviour
• Digital UX Optimisation
• Political and Public Communication

By End-User Industry

• FMCG and Consumer Goods
• Media and Entertainment
• Automotive
• Financial Services
• Healthcare and Pharma
• Government and Public Sector

By Deployment Mode

• Laboratory-Based
• Cloud-Based SaaS Platform
• Mobile and Wearable
• Integrated Research Agency

Frequently Asked Questions

Q1. What is the strongest near-term growth driver for neuromarketing technology investment? ▼

The deprecation of third-party cookies is the single clearest near-term catalyst, forcing brand advertisers to build direct psychological measurement capability. This is redirecting data budgets toward neuromarketing platforms faster than any previous industry event.

Q2. Which technology segment within neuromarketing is most attractive for new investment? ▼

AI-powered predictive analytics platforms represent the highest-return segment, as they eliminate hardware dependency and scale at software economics. Neurons Inc. and iMotions are the leading platforms capturing this shift.

Q3. How serious is the GDPR risk to European neuromarketing revenues? ▼

The risk is material and underpriced by most analysts. If the European Data Protection Board classifies commercial EEG and facial coding data under Article 9 sensitive data rules, European revenues — roughly 28% of the global market — face structural contraction within 24 months of any binding ruling.

Q4. Is the neuromarketing technology market recession-resilient? ▼

It is not. Neuromarketing research is discretionary spend within marketing budgets and contracts are among the first renegotiated during downturns, as demonstrated by the 2023 CPG budget correction. Investors should treat cyclical exposure as a genuine risk, not a theoretical one.

Q5. Which region offers the best risk-adjusted growth opportunity through 2034? ▼

Asia Pacific offers the highest absolute growth trajectory, led by China and South Korea, without the regulatory overhang that suppresses European upside. Vendors with established local partnerships in these markets will capture disproportionate share of the incremental revenue pool.